Prime Medicine, Inc. (PRME) valuation

  1. Home
  2. Financials
  3. PRME
  4. Valuation

Share price $3.48 · As of last filing 2026-03-31

Price-to-Earnings

P/E · Trailing Diluted
-2.78×
P/E history →

Price-to-Free-Cash-Flow

P/FCF · Trailing
-3.96×
P/FCF history →

Free-Cash-Flow Yield

FCF Yield · Trailing
-25.26%
FCF Yield history →

Enterprise-Value-to-EBITDA

EV/EBITDA · Trailing
-3.05×
EV/EBITDA history →

Underlying EBIT Margin

EBIT + SBC · Trailing
-3851.06%
Methodology →

Price-to-Sales

P/S · Trailing
135.70×
P/S history →

Price-to-Book

P/B · Latest filing
8.19×
P/B history →

What these ratios mean & how they're built: see the valuation ratios glossary on the Financials methodology page — per-ratio definitions and the exact us-gaap concepts behind each numerator and denominator.

Sources. Denominators come from SEC EDGAR XBRL filings for PRME (CIK 0001894562); analyst growth forecasts come from analyst consensus. Filing-anchored figures are rendered server-side at the split-adjusted close on the latest reported period-end — so every ratio reconciles to the same filing as every other figure on this page — and the share price, six ratio cards, EPV gap, and reverse-DCF outputs above re-anchor on the most recent daily close in the browser when JavaScript is enabled. The "Full calculation trail" sections stay anchored to the period-end close so the line-by-line arithmetic still reconciles. Per-share denominators are split-adjusted to today's share count.

Related tickers

ATI

ATI Inc.

HLIT

HARMONIC INC.

RELY

Remitly Global, Inc.